8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                             ----------------------

                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

                              --------------------

          Date of report (Date of earliest event reported): May 9, 2006

                            Applied DNA Sciences, Inc
               (Exact Name of Registrant as Specified in Charter)


           Nevada                   002-90539                  59-2262718
      (State or Other        (Commission File Number)        (IRS Employer
       Jurisdiction                                       Identification No.)
     of Incorporation)


                       25 Health Sciences Drive, Suite 113
                           Stony Brook, New York 11790
               (Address of Principal Executive Offices) (Zip Code)

                                  631-444-6861
              (Registrant's telephone number, including area code)

                                 Not Applicable
          (Former Name or Former Address, if Changed Since Last Report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2 below):

|_|   Written communications pursuant to Rule 425 under the Securities Act
      (17 CFR 230.425)

|_|   Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
      (17 CFR 240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13e-4(c))





Item 8.01 Other Events.

      On May 9, 2006,  Applied  DNA  Sciences,  Inc.  issued a press  release to
announce that it has entering into a Business  Development and Trademark License
Agreement with Dr. Suwelack Skin & Healthcare AG. A copy of the press release is
attached as Exhibit 99.1 to this Current Report on Form 8-K.


Item 9.01 Financial Statements and Exhibits

      (d)   Exhibits.

       Exhibit 99.1       Press  release  of  Applied DNA Sciences, Inc.,  dated
                          May 9, 2006.






                                    SIGNATURE

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                       Applied DNA Sciences, Inc.
                                       (Registrant)



                                       By: /s/ James  Hayward
                                       --------------------------------------
                                       James Hayward
                                       Chief Executive Officer




Date: May 9, 2006





Exhibit No.    Description of Exhibit
- -----------    ----------------------

99.1           Press Release of Applied DNA Sciences, Inc., dated May 9, 2006.

EX-99.1

                          applied DNA sciences [LOGO]
                            security solutions

    -----------------------------------------------------------------------

          APPLIED DNA SCIENCES SIGNS BUSINESS DEVELOPMENT AND TRADEMARK
            LICENSE AGREEMENT WITH DR. SUWELACK SKIN & HEALTHCARE AG

STONY BROOK, N.Y., May 9 /PRNewswire First Call / -- Applied DNA Sciences, Inc.
(OTC BB: APDN), a DNA security solutions company, announced that it signed an
agreement with Dr. Suwelack Skin & Healthcare AG ("Suwelack") providing Suwelack
rights to use APDN's SigNature(TM) logo, which is printed with ink containing
our proprietary encrypted botanical DNA technology, and to participate in its
SigNature(TM) Program. The terms of this one year license agreement provide
Suwelack with a limited, non-exclusive, non-transferable right to use the
SigNature(TM) logo on its packaging and labels.

Created by APDN, the goal of the SigNature(TM) Program is to provide a secure,
cost effective and forensic method to help companies like Suwelack protect their
intellectual property assets and the value of their brand. This program is based
on APDN's proprietary platform technology whereby nanoscopic botanical DNA is
embedded in a proprietary protective coating that withstands commercial
processing and gives DNA a life of several hundred years. Botanical DNA will be
embedded into the ink that will be used in the SigNature(TM) logo utilizing both
overt and covert DNA security technologies. This botanical DNA can later be
sequenced and decoded from the SigNature(TM) logo to verify the authenticity of
Suwelack's products.

Suwelack is recognized in Germany as the leader in the innovation, development
and manufacture of biomatrices for cosmeceutical and healthcare applications.
Suwelack has adopted the SigNature(TM) Program as one of many new initiatives
that complement its expansion into the North American market.





According to Nikolaus Uleer,  Chief Executive Officer of Suwelack,  "We are very
pleased to utilize DNA  encryption  technology in our  packaging.  It provides a
secure, forensic, and most importantly, cost effective approach, that we believe
will provide a positive contribution to the development of our brand."

The SigNature(TM) Program is the first initiative by APDN to introduce to the
market a range of ready-to-use security solutions aimed at brand protection and
authentication, and addressing the global need to combat counterfeit and piracy.

Dr. Benjamin Liang, Chief Scientist of Applied DNA Sciences, said "We believe
that our technology provides an immediate benefit and relevance to a company
like Suwelack that has applications in both skincare and healthcare. From a
business development perspective, we can deliver a fast-track security solution
intended to provide both strategic and tactical value to our clients. We are
pleased that Suwelack is our first commercial partner in Europe."

About Dr. Suwelack Skin & Healthcare AG

Dr. Suwelack Skin & Healthcare AG manufactures biomatrices for skin and
healthcare for cosmeceutical and medical applications. Suwelack's patented
technology uses a freeze-drying process to gently extract water from natural raw
materials, as a result of which the raw materials are preserved in a highly pure
form. By using this technique the company is able to avoid using preservative
agents, chemical cross-linking agents and perfumes and ensure the basis for skin
compatibility. Contact: Nikolaus Uleer, Dr. Suwelack Skin & Healthcare AG,
Josef-Suwelack-Strasse, 48727 Billerbeck, Germany Tel: +49-2543-72-247 Fax:
+49-2543-72-365 http://www.skin-healthcare.com

About Applied DNA Sciences, Inc.

Applied DNA Sciences, Inc. (APDN) develops proprietary DNA-embedded security
solutions that use plant DNA to verify authenticity and protect corporate and
government agencies from counterfeiting, fraud, piracy, product diversion,
identity theft and unauthorized intrusion into physical plant and databases. Our
common stock is listed on the Over-The-Counter Bulletin Board under the symbol
"APDN". Contact: MeiLin Wan, Applied DNA Sciences, Inc., 25 Health Sciences
Drive, Stony Brook, New York 11790; Tel: 631-444-6861; Fax: 631-444.8848;
E-mail: info@adnas.com www.ADNAS.com.





The statements made by Applied DNA Sciences, Inc. in this press release may be
forward-looking in nature and are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements describe the Company's future plans, projections, strategies and
expectations, and may be identified by words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates" or words of similar
meaning. These forward-looking statements are based on assumptions and involve a
number of risks, uncertainties, situations and other factors that may cause our
or our industry's actual results, level of activity, performance or achievements
to be materially different from any future results, level of activity,
performance or achievements expressed or implied by these statements. These
factors include changes in interest rates, market competition, changes in the
local and national economies, and various other factors detailed from time to
time in Applied DNA Sciences' SEC reports and filings, including our Annual
Report on Form 10-KSB, filed on January 12, 2006, and subsequent Quarterly
Reports on Form 10-QSB and Current Reports on Form 8-K. The Company undertakes
no obligation to update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof to reflect the
occurrence of unanticipated events.

SOURCE  Applied DNA Sciences, Inc.
   -0- 05/09/2006
   /CONTACT:  MeiLin Wan of Applied DNA Sciences, Inc., +1-631-444-6861, or
Fax: +1-631-444-8848, Email: info@adnas.com/
   /First Call Analyst: /
   /FCMN Contact: info@adnas.com /
   /Web site: http://www.ADNAS.com /
   (APDN)